Brentuximab Vedotin in Transplant‐Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies

• Published in: The oncologist (Dayton, Ohio) Vol. 17; no. 8; pp. 1073 - 1080
• Main Authors: Forero‐Torres, Andres, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L., Rosenblatt, Joseph D., Kennedy, Dana A., Younes, Anas
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 01.08.2012
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antigens CD30; Child; Clinical Trials, Phase I as Topic; Female; Hodgkin disease; Hodgkin Disease - drug therapy; Hodgkin Disease - pathology; Humans; Immunoconjugates; Immunoconjugates - adverse effects; Immunoconjugates - therapeutic use; Ki-1 Antigen - metabolism; Lymphoma; Male; Middle Aged; Monoclonal antibodies; Neoplasm Staging; Oligopeptides - therapeutic use; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2012-0133

Background. Brentuximab vedotin is an antibody‐drug conjugate designed to selectively deliver monomethyl auristatin E, a microtubule‐disrupting agent, to CD30‐expressing cells. Brentuximab vedotin induces durable objective responses in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). The objective of this post‐hoc analysis was to characterize the safety and efficacy of brentuximab vedotin for patients with relapsed or refractory HL who refused or were ineligible for ASCT. Methods. This case series included 20 transplant‐naïve patients who were enrolled in two phase I multicenter studies. Patients received brentuximab vedotin intravenously every 3 weeks or every week for 3 out of 4 weeks. Results. The majority of patients were transplant‐naïve because of chemorefractory disease. Median age was 31.5 years (range, 12–87 years). Treatment‐emergent adverse events in >20% of patients were peripheral neuropathy, fatigue, nausea, pyrexia, diarrhea, weight decreased, anemia, back pain, decreased appetite, night sweats, and vomiting; most events were grade 1 or 2. Six patients obtained objective responses: two complete remissions and four partial remissions. Median duration of response was not met; censored durations ranged from >6.8 to >13.8 months. Three of six responders subsequently received ASCT. Conclusion. Brentuximab vedotin was associated with manageable adverse events in transplant‐naïve patients with relapsed or refractory HL. The objective responses observed demonstrate that antitumor activity is not limited to patients who received brentuximab vedotin after ASCT. The promising activity observed in this population warrants further study. This post‐hoc analysis aims to characterize the safety and efficacy of brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma who refused or were ineligible for autologous stem cell transplantation.